{"id":3410,"date":"2024-12-17T12:34:23","date_gmt":"2024-12-17T18:34:23","guid":{"rendered":"https:\/\/www.molllawgroup.com\/blog\/?p=3410"},"modified":"2024-12-17T12:34:23","modified_gmt":"2024-12-17T18:34:23","slug":"oxbryta-litigation-has-commenced","status":"publish","type":"post","link":"https:\/\/www.molllawgroup.com\/blog\/oxbryta-litigation-has-commenced\/","title":{"rendered":"Oxbryta Litigation Has Commenced"},"content":{"rendered":"

\"treatment-4099432_6402-e1734460206805\"Recently, a medication for sickle cell disease, Oxbryta, was voluntarily recalled<\/a> because it can cause complications and death. Litigation has begun against Pfizer Inc. and its subsidiary Global Therapeutics. One plaintiff, a patient who underwent treatment, has alleged that the companies should have known that administration of the sickle cell treatment could result in a patient\u2019s death. According to that plaintiff, he suffered a higher rate of vaso-occlusive crisis after he used the medication. Pfizer denies that it acted irresponsibly. If you were harmed by Oxbryta, give the seasoned Chicago-based dangerous drug lawyers of Moll Law Group a call.<\/p>\n

Call Moll Law Group About Your Oxbryta Claim<\/strong><\/p>\n

Oxbryta is a drug that was meant to alleviate sick cell disease symptoms. It was formulated to prevent hemoglobin polymerization; this, in turn, stops the sickling of red blood cells and improving the ability for hemoglobin to be oxygenated. In 2019, the Food and Drug Administration (FDA) accelerated its approval for those patients who are at least 12-years-old. In 2021, the FDA approved the drug for children with the minimum age for use being age 4. Unfortunately, once the drug was used in the real world, certain side effects were dire. One of the complications that arose in connection with the drug were vaso-occlusive crises, painful incidents where the sickled blood cells obstruct the flow of blood through a patient\u2019s body. Some patients died as a result of these complications.<\/p>\n

Pfizer recalled the drug across the world in September 2024, due to this real-world data that indicated Oxbryta\u2019s risks are greater than its potential benefits. Patients and family members brought many lawsuits against Pfizer, and many of these claimed that Pfizer and its subsidiary had failed to provide adequate warnings as to these risks and complications. In plain terms, they are arguing that the company didn\u2019t let them know about the risk of suffering vaso-occlusive crises and death and this prevented doctors and patients from making informed decisions about whether or not to take the drug.<\/p>\n

Continue reading \u2192<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Recently, a medication for sickle cell disease, Oxbryta, was voluntarily recalled because it can cause complications and death. Litigation has begun against Pfizer Inc. and its subsidiary Global Therapeutics. One plaintiff, a patient who underwent treatment, has alleged that the companies should have known that administration of the sickle cell treatment could result in a […]<\/p>\n","protected":false},"author":2,"featured_media":3411,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[19,3],"tags":[],"class_list":["post-3410","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-dangerous-products","category-product-liability"],"yoast_head":"\nOxbryta Litigation Has Commenced — Illinois Injury and Mass Tort Lawyer Blog — December 17, 2024<\/title>\n<meta name=\"description\" content=\"Recently, a medication for sickle cell disease, Oxbryta, was voluntarily recalled because it can cause complications and death. Litigation has begun — December 17, 2024\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.molllawgroup.com\/blog\/oxbryta-litigation-has-commenced\/\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"Oxbryta Litigation Has Commenced — Illinois Injury and Mass Tort Lawyer Blog — December 17, 2024\" \/>\n<meta name=\"twitter:description\" content=\"Recently, a medication for sickle cell disease, Oxbryta, was voluntarily recalled because it can cause complications and death. Litigation has begun — December 17, 2024\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.molllawgroup.com\/blog\/wp-content\/uploads\/2024\/12\/treatment-4099432_6402-e1734460206805.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Moll Law Group\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Oxbryta Litigation Has Commenced — Illinois Injury and Mass Tort Lawyer Blog — December 17, 2024","description":"Recently, a medication for sickle cell disease, Oxbryta, was voluntarily recalled because it can cause complications and death. Litigation has begun — December 17, 2024","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.molllawgroup.com\/blog\/oxbryta-litigation-has-commenced\/","twitter_card":"summary_large_image","twitter_title":"Oxbryta Litigation Has Commenced — Illinois Injury and Mass Tort Lawyer Blog — December 17, 2024","twitter_description":"Recently, a medication for sickle cell disease, Oxbryta, was voluntarily recalled because it can cause complications and death. Litigation has begun — December 17, 2024","twitter_image":"https:\/\/www.molllawgroup.com\/blog\/wp-content\/uploads\/2024\/12\/treatment-4099432_6402-e1734460206805.jpg","twitter_misc":{"Written by":"Moll Law Group","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.molllawgroup.com\/blog\/oxbryta-litigation-has-commenced\/#article","isPartOf":{"@id":"https:\/\/www.molllawgroup.com\/blog\/oxbryta-litigation-has-commenced\/"},"author":{"name":"Moll Law Group","@id":"https:\/\/www.molllawgroup.com\/blog\/#\/schema\/person\/53d2eb37d5d0cdb46ac61abacf05ce90"},"headline":"Oxbryta Litigation Has Commenced","datePublished":"2024-12-17T18:34:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.molllawgroup.com\/blog\/oxbryta-litigation-has-commenced\/"},"wordCount":523,"image":{"@id":"https:\/\/www.molllawgroup.com\/blog\/oxbryta-litigation-has-commenced\/#primaryimage"},"thumbnailUrl":"https:\/\/www.molllawgroup.com\/blog\/wp-content\/uploads\/2024\/12\/treatment-4099432_6402-e1734460206805.jpg","articleSection":["Dangerous Products","Product Liability"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.molllawgroup.com\/blog\/oxbryta-litigation-has-commenced\/","url":"https:\/\/www.molllawgroup.com\/blog\/oxbryta-litigation-has-commenced\/","name":"Oxbryta Litigation Has Commenced — Illinois Injury and Mass Tort Lawyer Blog — December 17, 2024","isPartOf":{"@id":"https:\/\/www.molllawgroup.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.molllawgroup.com\/blog\/oxbryta-litigation-has-commenced\/#primaryimage"},"image":{"@id":"https:\/\/www.molllawgroup.com\/blog\/oxbryta-litigation-has-commenced\/#primaryimage"},"thumbnailUrl":"https:\/\/www.molllawgroup.com\/blog\/wp-content\/uploads\/2024\/12\/treatment-4099432_6402-e1734460206805.jpg","datePublished":"2024-12-17T18:34:23+00:00","author":{"@id":"https:\/\/www.molllawgroup.com\/blog\/#\/schema\/person\/53d2eb37d5d0cdb46ac61abacf05ce90"},"description":"Recently, a medication for sickle cell disease, Oxbryta, was voluntarily recalled because it can cause complications and death. Litigation has begun — December 17, 2024","breadcrumb":{"@id":"https:\/\/www.molllawgroup.com\/blog\/oxbryta-litigation-has-commenced\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.molllawgroup.com\/blog\/oxbryta-litigation-has-commenced\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.molllawgroup.com\/blog\/oxbryta-litigation-has-commenced\/#primaryimage","url":"https:\/\/www.molllawgroup.com\/blog\/wp-content\/uploads\/2024\/12\/treatment-4099432_6402-e1734460206805.jpg","contentUrl":"https:\/\/www.molllawgroup.com\/blog\/wp-content\/uploads\/2024\/12\/treatment-4099432_6402-e1734460206805.jpg","width":600,"height":400},{"@type":"BreadcrumbList","@id":"https:\/\/www.molllawgroup.com\/blog\/oxbryta-litigation-has-commenced\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.molllawgroup.com\/blog\/"},{"@type":"ListItem","position":2,"name":"Oxbryta Litigation Has Commenced"}]},{"@type":"WebSite","@id":"https:\/\/www.molllawgroup.com\/blog\/#website","url":"https:\/\/www.molllawgroup.com\/blog\/","name":"Illinois Injury and Mass Tort Lawyer Blog","description":"Published by Illinois Injury and Mass Tort Attorney \u2014 Moll Law Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.molllawgroup.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.molllawgroup.com\/blog\/#\/schema\/person\/53d2eb37d5d0cdb46ac61abacf05ce90","name":"Moll Law Group","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/0febdc96ea554e620e775358f9d7e4fc56616188dfd2bb21b18c2fed4bd185a0?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/0febdc96ea554e620e775358f9d7e4fc56616188dfd2bb21b18c2fed4bd185a0?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/0febdc96ea554e620e775358f9d7e4fc56616188dfd2bb21b18c2fed4bd185a0?s=96&d=mm&r=g","caption":"Moll Law Group"}}]}},"jetpack_featured_media_url":"https:\/\/www.molllawgroup.com\/blog\/wp-content\/uploads\/2024\/12\/treatment-4099432_6402-e1734460206805.jpg","_links":{"self":[{"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/posts\/3410","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/comments?post=3410"}],"version-history":[{"count":5,"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/posts\/3410\/revisions"}],"predecessor-version":[{"id":3416,"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/posts\/3410\/revisions\/3416"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/media\/3411"}],"wp:attachment":[{"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/media?parent=3410"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/categories?post=3410"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.molllawgroup.com\/blog\/wp-json\/wp\/v2\/tags?post=3410"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}